| Replication fork stability confers chemoresistance in BRCA-deficient cells A Ray Chaudhuri, E Callen, X Ding, E Gogola, AA Duarte, JE Lee, ... Nature 535 (7612), 382-387, 2016 | 820 | 2016 |
| The human CD38 monoclonal antibody daratumumab shows antitumor activity and hampers leukemia–microenvironment interactions in chronic lymphocytic leukemia A Matas-Céspedes, A Vidal-Crespo, V Rodriguez, N Villamor, J Delgado, ... Clinical Cancer Research 23 (6), 1493-1505, 2017 | 59 | 2017 |
| Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells S Body, A Esteve-Arenys, H Miloudi, C Recasens-Zorzo, G Tchakarska, ... Scientific reports 7 (1), 13946, 2017 | 48 | 2017 |
| Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens A Vidal-Crespo, A Matas-Céspedes, V Rodriguez, C Rossi, JG Valero, ... Haematologica 105 (4), 1032, 2020 | 42 | 2020 |
| Disruption of follicular dendritic cells–follicular lymphoma cross-talk by the Pan-PI3K inhibitor BKM120 (Buparlisib) A Matas-Céspedes, V Rodriguez, SG Kalko, A Vidal-Crespo, L Rosich, ... Clinical Cancer Research 20 (13), 3458-3471, 2014 | 34 | 2014 |
| The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational … A Vidal-Crespo, V Rodriguez, A Matas-Cespedes, E Lee, ... Haematologica 102 (11), e447, 2017 | 19 | 2017 |
| Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia E Lee‐Vergés, BS Hanna, H Yazdanparast, V Rodríguez, ML Rodríguez, ... International journal of cancer 144 (11), 2762-2773, 2019 | 15 | 2019 |
| Daratumumab, a novel human anti-CD38 monoclonal antibody for the treatment of chronic lymphocytic leukemia and B-cell non–Hodgkin lymphoma A Matas-Céspedes, A Vidal-Crespo, V Rodriguez, G Roue, E Campo, ... Blood 120 (21), 3935, 2012 | 13 | 2012 |
| Daratumumab, a novel anti-CD38 monoclonal antibody shows anti-tumor activity in CLL and hampers leukemia-microenvironment interactions A Matas-Céspedes, A Vidal-Crespo, V Rodriguez, J Delgado, N Villamor, ... Blood 124 (21), 4680, 2014 | 5 | 2014 |
| the novel BTK inhibitor CC-292 exerts in vitro and in vivo antitumor activity, interferes with adhesion, cell migration, and synergizes with lenalidomide in MCL models A Vidal-Crespo, V Rodríguez, A Matas-Céspedes, E Campos, ... Cancer Research 74 (19_Supplement), 1757-1757, 2014 | 3 | 2014 |
| The novel BTK inhibitor CC-292 exerts antitumor activity, inhibits proliferation, activation and migration of tumor cells, and overcomes stroma-mediated chemoresistance to … E Lee, V Rodriguez, B Hanna, H Yazdanparast, M Rodriguez, V Amador, ... LEUKEMIA & LYMPHOMA 58, 117-118, 2017 | | 2017 |
| DARATUMUMAB, A NOVEL HUMAN CD38 MONOCLONAL ANTIBODY FOR THE TREATMENT OF B-CELL NON-HODGKIN LYMPHOMA A Matas-Cespedes, A Vidal-Crespo, V Rodriguez, C Rossi, G Roue, ... HAEMATOLOGICA 102, 563-563, 2017 | | 2017 |
| ANTI‐TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO AND IN VIVO MODELS OF B‐CELL NON … P Pérez‐Galán, A Vidal‐Crespo, A Matas‐Céspedes, V Rodriguez, ... Hematological Oncology 35, 46-47, 2017 | | 2017 |
| Targeting the crosstalk between tumor cells and microenvironment: a new therapeutic approach for the treatment of lymphoid neoplasms A Vidal Crespo Universitat de Barcelona, 2017 | | 2017 |
